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Abstract 
 
Peripheral artery disease (PAD) affects 8 to 10 million Americans, and the incidence of PAD is 
expected to increase as the population ages.  A high percentage of the PAD is undiagnosed prior 
to the onset of a serious cardiovascular event; therefore, the inability to screen and diagnose for 
PAD in the early stages could hinder efforts to decrease adverse consequences of cardiovascular 
disease.  Individuals with PAD have a 3 to 5 times increased risk of cardiovascular disease 
(CVD) mortality when compared to people without PAD.  Guided by the Stetler model, the 
purpose of this project was to evaluate the relationship between level of PAD, as measured by 
skin perfusion pressure, and HbA1c using secondary data obtained from charts of patients within 
the clinic setting.    Data included patient gender, age, degree of PAD, and HbA1c.  A Pearson’s 
correlation investigated the relationship between the patients’ HbA1c and level of PAD.  There 
was a significant relationship between HbA1c and LT PAD (r = .21, p =.009).  There was no 
relation in RT PAD (r =.01, n = 149, p = .90).  There was a significant relationship between 
HbA1c and age (r = .34, p = .00). Ultimately, the goal of this study was to improve PAD 
recognition, encourage early intervention, and facilitate effective preventive methods.  Critical 
limb ischemia might be delayed or prevented if it is identified earlier by screening 
methodologies. Early identification and treatment of PAD can improve the quality of life and 
care for individuals suffering with PAD.     
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Section 1: Screening for Peripheral Artery Disease 
Peripheral artery disease (PAD) affects 8 to 10 million Americans and it is expected to 
increase as the population ages and chronic diseases continue to rise (Hirsch, Hartman, Town & 
Virnig, 2008).  Peripheral artery disease is defined as atherosclerosis of the abdominal aorta, 
iliac, and lower-extremity arteries (Olin & Sealove, 2010).  According to the Sage Group (2010), 
the direct cost of PAD in the United States has been estimated to be between $164 and $290 
billion dollars.  According to the U.S. Preventive Services Taskforce (USPTF), PAD is a 
manifestation of systemic atherosclerosis that has demonstrated a significant correlation with 
other atherosclerotic, cardiovascular diseases (CVD) and cardiac related events (USPTF, 2013).  
A high percentage of the PAD population is undiagnosed before a serious cardiovascular event; 
therefore, the ability to screen and diagnose this disease could have a dramatic impact on the 
efforts to decrease cardiovascular disease (Norgren et al., 2010).  Individuals with PAD have a 
three to five times increased risk of CVD mortality when compared to people who do not have 
PAD (Criqui et al., 1992). 
There is a high prevalence of PAD in the primary care setting but the diagnosis by 
providers is relatively low.  Patients with PAD have similar arteriosclerotic risk factors such as 
hyperlipidemia, hypertension, and diabetes but they received less intensive treatments unlike 
patients with confirmed CVD (Hirsch et al., 2001).  The underdiagnosis of PAD in primary care 
practice could be a barrier to effective secondary prevention of the high ischemic cardiovascular 
risk associated with PAD (Hirsch et al., 2001). 
Additionally, the consistent correlation between PAD and future CVD events has 
influenced the American Heart Association (AHA) and the National Cholesterol Education 
Program (NCEP) to establish recommendations for intensive atherosclerotic risk factor reduction 
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for PAD and CVD patients (NCEP, 1993).  Early identification of patients with PAD has the 
potential to impact CVD and, in doing so, to create opportunities for aggressive management of 
the risk factors leading to this disease.  Common disease and lifestyle factors have been directly 
linked to PAD and CVD; therefore, health promotion has been focused on risk reduction (AHA, 
2013). 
Significant strides have been made in the risk reduction of this disease through 
modification of health behaviors such as tobacco use, sedentary lifestyle, and obesity (Spring et 
al., 2013).  Disease management of hypertension, diabetes, and hyperlipidemia has proven to 
have significant impact on atherosclerosis (Olin & Sealove, 2010).  Secondary prevention 
involves screening for diseases before they have had an impact on the individual.  Screening 
high-risk patients with diabetes and hypertension who are asymptomatic for PAD is an example 
of secondary prevention.  The ultimate goal of prevention is to impact the prevalence and 
incidence of disease.  
The ability to access care has a profound effect on an individual’s health.  One in four 
Americans does not have a primary care practitioner or insurance for medical care (U.S. 
Government of Health and Human Services, 2013).  This disparity leads to decreased access to 
preventive health initiatives.  In 2002, Dillingham, Pezzin, and MacKenzie demonstrated an 
increased risk of amputations with age for all comorbidities and were highest among blacks with 
CLI amputations.  The risk of amputations was increased among elderly and minority 
populations, is of concern and warrants further investigation. Clinical preventive services such as 
screening for disease are necessary for the prevention of chronic diseases, such as hypertension, 
diabetes and various cancers (U.S. Government of Health and Human Services, 2013). 
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Purpose Statement 
The purpose of this project was to evaluate whether there is a relationship between  
glycosylated hemoglobin (HbA1c) levels and peripheral flow or PAD severity measured with 
skin perfusion pressures (SPP).  Glycosylated hemoglobin is a lab test that represents the 
patient’s average level of blood glucose over the previous three months.  A normal value is less 
than 5.7%; higher numbers of 7.0% or greater represent a lack of glycemic control which causes 
significant changes to the vasculature of diabetic patients (American Diabetes Association, 
2014).  The purpose of this study was to evaluate whether there is a relationship between skin 
perfusion pressures (SPP) and HbA1c. 
Currently, the evidence does not support the screening of asymptomatic patients, but this 
study will attempt to look at early screening and its impact in the identification of PAD (USPTF, 
2013).  Early identification of PAD can lead to a decrease in the development of severe CVD 
through initiation of early prevention and intervention strategies.   
Project Objectives 
The objectives for this evidence-based project are as follows: 
1. Evaluate the relationship between HbA1c levels and PAD severity. 
2. Add to the current literature on Diabetes and PAD. 
3. Highlight the importance of tight glycemic control. 
Guiding Practice 
Practitioners do not routinely screen for PAD, unless there are complaints of claudication, 
or signs of PAD, which includes hairless lower extremities, decreased peripheral pulses, and 
limb coolness.  Symptomatic patients receive screening using ankle brachial index (ABI), which 
provides information about limb perfusion using a blood pressure ratio between the arm and the 
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leg (Mukherjee & Cho, 2009).  Pulse volume waveform analysis is another technique that is used 
to evaluate the extent of PAD.  This project has the potential to decrease the gaps in the evidence 
related to late recognition of the problem.  Early recognition could lead to prevention of disease 
progression and timely intervention (Hirsch et al., 2006). 
Significance of the Project 
Reduction of Gaps 
The gaps in access to care would be reduced and gaps in the literature regarding PAD and 
HBA1c correlation would be decreased.  This would help to reduce the disparities in the access 
to care and would also provide support for early screening of asymptomatic patients. 
Implications for Social Change 
By providing access to care with early screening, the community would see a marked 
decrease in the cost of PAD care.  This would also result in a decrease in the number of 
amputations due to PAD.  Additionally, the end result could potentially prevent cardiovascular 
disease.  
Definition of Terms 
 
Table 1 
Definition of Terms  
 
Medical Term Abbreviation Definition of Term 
PAD peripheral artery disease 
ABI ankle brachial index 
SPP skin perfusion pressure 
CLI critical limb ischemia 
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Assumptions, limitations and delimitations   
Secondary data collected have inherent assumptions about the measurement and 
reliability of the data collected.  The skin perfusion pressure (SPP) testing was completed by the 
various clinic assistants and, therefore, there may be inconsistencies in the screening.  The 
studies were read by providers at all the clinics and there could be a reader bias towards over-
reading or under-reading the SPP.  
Limitations        
 There were three limitations to this project.  Primarily, the correlation between HbA1c 
and PAD disease level had not been studied previously.  Secondly, asymptomatic patients had 
not been studied previously and were not recognized as current practice in the literature.  
Thirdly, this study should include a longitudinal assessment in order to obtain outcomes that can 
truly be broadly generalized; therefore, the short timeframe of this study not producing as much 
data as was needed was a limitation.  
Summary 
This project set out to evaluate whether or not there was a relationship between peripheral 
artery disease and glycemic control.  The secondary data of patients with diabetes and 
hypertension were evaluated and screened for peripheral artery disease (PAD). 
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Section 2: Review of Literature and Theoretical and Conceptual Framework 
 Review of Literature 
A review of the literature was conducted using Cumulative Index to Nursing and Allied 
Health (CINAHL) and Medline Plus.  The search was limited to the years 1992 to 2014.  The key 
words used in the search were peripheral artery disease, PAD, critical limb ischemia and 
screening.  The studies were reviewed and used to clarify the significance of PAD and to identify 
the limitations of symptomatic screening.  Furthermore, the literature review demonstrated the 
importance of exploring asymptomatic screening. 
Literature Related to Peripheral Artery Disease 
 Peripheral vascular disease has a negative physical and psychological effect on 
individuals who are struggling to save a limb.  Critical limb ischemia (CLI) can lead to 
amputations, which can affect an individual’s ability to make a living.  Critical limb ischemia is 
defined as chronic ischemia causing pain at rest, ulcers and or gangrene, which can be attributed 
to long-standing arterial occlusion.  Ziegler-Graham, MacKenzie, Ephraim, Travison, and 
Brookmeyer (2008) reported that in the year 2005, 1.6 million people were living with the loss of 
a limb. Additionally, 42% were nonwhite and 38% had an amputation caused by diabetes related 
vascular disease (Ziegler-Graham et al., 2008).  In their study they projected that the number of 
people living with limb loss will more than double up to 3.6 million people by the year 2050.  
Additionally, if the rate of secondary vascular disease can be reduced by 10%, this number 
would be lowered by 225,000 (Ziegler-Graham et al., 2008). 
According to Sprengers et  al. (2010), critical limb ischemia will develop in 500 to 1000 
patients in a Western population of one million people and will lead to surgeries, 
hospitalizations, deaths and 5-year survival rates of only 50%.  Peripheral  artery disease and 
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CLI creates functional impairments for the population, which can affect their psychological well-
being.  Stauber et al. (2013) demonstrated significant relationships between disease severity and 
the psychological risk factors of depression, anxiety, and type D personality (a tendency towards 
negativity)  in a cross-sectional study.  Patients with PAD and depression had an increased 
decline in their physical functionality than patients without depression (Ruo et al., 2007).  The 
chronicity of the disease and the severity of the pain impacted the individual’s ability to cope and 
to complete daily activities.  Stauber et al. discovered higher levels of depression in patients with 
PAD than those with CVD. Peripheral artery disease patients with higher levels of depression 
also have greater revascularization failure rates, which lead to additional difficulties in their 
ability to manage their condition (Stauber et al., 2013).  
Baser, Verpillat, Gabriel, and Wang (2013) analyzed the annual prevalence and incidence 
of CLI in the elderly population in the United States by retrospectively collecting and analyzing 
clinical characteristics from January 2007 to December 2008 Medicare beneficiaries.  Their 
analysis revealed that patients over the age of 65 years had an overall prevalence and incidence 
rate of CLI at 0.23% and 0.20% respectively.  This result was constant in each year.  The age-
specific annual rates, demonstrated a rise in prevalence and incidence in patients from 65 years 
to 69 years of age (prevalence: 0.15%, incidence: 0.13%) to patients aged 85 and older 
(prevalence: 0.36%, incidence: 0.31%).  
Literature Regarding Preventing Arterial Disease 
The Healthy People 2020 is a national initiative for health promotion and disease 
prevention.  The goal of Healthy People 2020 is to improve health by removing disparities and 
creating environments which promote health. 
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The goal of the Healthy People 2020 is to decrease the number of limb amputations in 
people with diabetes.  In 2013, the U.S. Preventive Services Task Force (USPSTF) gave a 
recommendation D, or fair level of evidence, to screening for PAD in asymptomatic patients, 
proving a guideline for providers.  McDermott et al. (2009) demonstrated that 19.8% of the 
study’s patients had no exertional leg pain, 28.5% had atypical leg pain, 32.6% had classic 
intermittent claudication, and 19.1% had pain at rest.  Asymptomatic disease may be present in 
up to 50% of patients with PAD (Hirsch et al., 2008).  The American Heart Association (AHA) 
estimated that over 8 million Americans have PAD and more than 75% of these individuals do 
not have symptoms (USPSTF, 2013).  
In an effort to prevent PAD severity and its complications, the American Diabetes 
Association (ADA) recommends annual screening for individuals with diabetes.  The American 
College of Cardiology (ACC) and the American Heart Association (AHA) recommends PAD 
screening using a resting ABI to diagnose patients’ suspected for lower extremity PAD (Rooke et 
al., 2011).  Patients presenting with symptoms of pain or cramping during ambulation, 
nonhealing wounds, diabetes, and smoking should be screened (Rooke et al., 2011).  However, it 
is often too late to screen at-risk populations when they are symptomatic, as the vascular damage 
has already occurred.   
Fowkes et al. (2013) compared of the prevalence of peripheral artery disease (PAD) 
between high-income countries (HIC) and low-income or middle-income countries (LMIC).  The 
prevalence of PAD in HIC at age 45–49 years was 5% to 28% in women and 5% to 41% in men.  
The prevalence of PAD in HIC  in older adults 85–89 years of age was 18% to 38% in women 
and 18% to 83% in men.  Also, smoking was an important risk factor in both HIC and LMIC, 
followed by diabetes, hypertension, and hypercholesterolemia.  
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Researchers have supported supervised exercise programs (level of evidence A) for the 
management of PAD (Rooke et al., 2011).  Supervised exercise programs can improve arterial 
insufficiency thus improving oxygen delivery to the tissue and improving gait (Rooke et al., 
2011).  Rehabilitation programs will be beneficial for PAD management, as well as the effects of 
the psychological functionality of the disease.  Therefore, the ability to screen high-risk patients 
for PAD before symptoms develop should decrease adverse PAD vascular and psychological 
effects.  Early detection of PAD will lead to less invasive and less costly treatment modalities.  
Contributing factors to PAD include coronary artery disease, diabetes, smoking, hypertension, 
and obesity.  Individually and cumulatively, these factors have a significant impact on the health 
of our population.   
Literature Regarding Diabetes and Peripheral Artery Disease 
Researchers have note reported a correlational study of glucose control and incidence 
PAD disease levels.  Yokoyama et al., (2011) reported significant improvement in outcomes with 
evidence based disease management.  Yokoyama et al. found incidences of composite, coronary 
heart disease, ischemic stroke, and peripheral artery disease (per 1000 person-years, 95% 
confidence interval).  The study results were 8.3 (6.6–10.0), 4.4 (3.2–5.6), 3.1 (2.1–4.2), and 0.7 
(0.2–1.2), respectively.  Each incidence was lower in the Yokoyama et al. study compared with 
other cohort studies (P < 0.01 compared to each cohort).  Significant variables predictive of the 
occurrence of cardiovascular events were age, duration of diabetes, HbA1c, HDL cholesterol, 
and urinary albumin (Yokoyama et al., 2011).  Additionally, lower HbA1c levels significantly 
contributed to a reduced incidence of cardiovascular disease (Yokoyama et al., 2011).   
The Factores de Riesgo y ENfermedad Arterial (FRENA) is a registry of stable 
outpatients with symptomatic coronary artery disease, cerebrovascular disease, or peripheral 
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artery disease to compare the incidence of subsequent myocardial infarctions, strokes or critical 
limb ischemia events.  Camafort et al. (2011) used data from FRENA and evaluated patients with 
type 2 diabetes and mean HbA1c levels < 7.0%   compared to  those with HbA1c levels > 7.0%.  
Of the 974 patients with type 2 diabetes, 480 (49%) had mean HbA1c levels < 7%.  Follow-up at 
14 months reported 126 patients (13%) had subsequent ischemic events: myocardial infarction (n 
= 43), stroke (n = 29) and critical limb ischemia (n = 64).  The incidence of subsequent ischemic 
events was significantly lower in patients with mean HbA1c levels of < 7.0% in those with 
HbA1c levels > 7.0% (Camafort et al., 2011). 
Diabetes, hypertension, hypercholesterolemia, and smoking can lead to PAD and if left 
untreated, may lead to critical limb ischemia (Rooke et al., 2011).  The U.S. Preventive Services 
Task Force (USPSTF) reported in 2013 that PAD based on ankle-brachial blood pressure (ABI) 
screening ratios occurs in between 10% to 20% of the population aged 65 years and older and 
18% to 29% of patients aged 50 and older in general medical practices. The diagnosis of PAD in 
diabetic patients is especially challenging because of the manner in which it presents. The ability 
to assess severity of PAD is altered because of the clinical presentation and the limitations of 
diagnostic procedures (Schaper et al., 2012). Screening of high-risk populations using non -
invasive technology has the potential to decrease the prevalence of PAD and provide critical 
information about the potential for CVD.  
Evidence-Based Model 
The Stetler (2001) model provides a foundation to guide research utilization for the 
creation of evidence-based practice (Burns & Grove, 2009).  This framework can be used to 
support, develop, and influence practice decisions.  This model supports institutional and policy 
makers’ use of the evidence to facilitate evidence-based practice (Burns & Grove, 2009).  The 
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Stetler model of evidence-based practice provides a framework, which allows for integration of 
research into practice.  The model is designed to assist with critical assessments of the literature, 
planning and implementation of the evidence.  The relevant research is linked to the problem 
addressed through synthesis and appraisal of the literature. This model includes the following 
steps:  preparation, validation, comparative evaluation of the literature, translation, and 
evaluation.  Preparation requires critical consideration of the purpose, focus and potential 
outcomes of the implementation (Burns & Grove, 2009).  Validation involves critical appraisal 
of the literature to determine the strength of the evidence and to ensure significance to the 
practice problem.  Comparative evaluation looks at the state of the evidence along with the 
setting to ensure research application and currency with nursing practice (Burns & Grove, 2009).  
The translation phase determines how the research will be applied to practice.  A pilot unit 
should be selected to evaluate the implementation and feasibility for generalization across the 
institution.  The evaluation phase involves data gathering through formal and informal 
evaluations of the evidence-based project.  The Stetler model (Figure 1) was used to facilitate the 
literature review, validate and synthesize the current literature on PAD.  There was evaluation of 
the literature based on currency with practice and the information garnered was used to 
substantiate the need for research.  The Stetler model was used to implement the screening of 
asymptomatic patients with diabetes and hypertension.  The data collected were analyzed and the 
results evaluated. 
  
12 
 
  
 
 
 
 
 
 
 
 
 
 
Figure 1. EBP using Stetler Model as the conceptual framework 
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Section 3: Methodology 
Retrospective Cohort Study 
The primary research method used in this project was a correlational retrospective cohort 
study.  This correlational retrospective cohort study evaluated the impact of early screening for 
PAD disease outcomes along with the relationship between HbA1cs and severity of disease.  A 
cohort study requires following one or more groups based on intervention or environmental 
factors over time.  There are two types of cohort studies: prospective and retrospective.  In a 
prospective study, the researcher collects baseline data from the study group in the present and 
outcomes data in the future (Friis & Sellers, 2009).  A retrospective study requires the researcher 
to gather data from the past and then collect outcomes data from the past or the present (Friis & 
Sellers, 2009).  For this study, a retrospective chart review was conducted looking for patients 
with diabetes, hypertension and the diagnosis of peripheral artery disease in the Corpus Christi, 
Texas area Christus Spohn Health System, which provided a convenience sample for the study.  
The Christus Spohn Health System is currently in the process of implementing PAD screening in 
several rural clinics as an adjunct to facilitate timely access to specialty care for this vulnerable 
population.    
The Delivery System Reform Incentive Payment (DSRIP) project is part of the 
government’s initiative to improve patient outcomes and the data collected for this project is 
available in the public domain.  As part of the DSRIP initiative, clinic patients with diabetes and 
hypertension were screened using the PAD-IQ.  This device is noninvasive and uses segmental 
pressure to obtain Skin Perfusion Pressure (SPP) to provide a quantitative evaluation of 
microcirculatory perfusion of the skin.  Clinic patients with diabetes and hypertension were 
screened using the PAD-IQ for PAD.  The device was noninvasive and used segmental pressure 
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to obtain SPP, which provided a quantitative evaluation of microcirculatory perfusion of the 
skin.  The segmental volume plethysmography was used to obtain Pulse Volume Recording 
(PVR), which provided information about the variations in the volume of blood passing through 
a limb during each cardiac cycle (Vasamed SensiLase PAD-IQ, 2013).  The waveform provided 
a pictorial view of the macro circulation.  This device can be used to obtain the traditional ankle 
brachial index (ABI) (Vasamed SensiLase PAD-IQ, 2013).  SPP was used to localize specific 
arteries causing limb ischemia, document limb revascularization post intervention and to assess 
wound healing.  This population based sample was categorized according to mild, moderate and 
severe disease.  Adequate perfusion was greater than 70 mm Hg; mild disease has SPP of 40 to 
60 mm Hg, moderate disease has an SPP of 30-40 mmHg, and severe disease has an SPP of less 
than 30 mm Hg.   
A retrospective chart review was conducted for baseline data abstraction of asymptomatic 
patients screened for PAD and their confidentiality was maintained by de-identification before 
analysis (Burns & Grove, 2009).  Data abstraction was conducted to obtain the HbA1c levels in 
the diabetic patients through chart reviews and trended with the level of PAD indicated by the 
SPP pressures.  Disease levels were correlated with HgA1cs for the sample. 
 Correlational studies provided information about the strength and direction of 
relationships between variables.  The higher the confidence level, the higher the strength of the 
relationships.  Analysis of the data provided clarification of theoretical concepts and possible 
identification of causal relationships. 
 
 
 
15 
 
Setting and Sample  
 The Christus Spohn Family Health Clinics (FHCs) implemented the PAD-IQ in all 
facilities as part of the DSRIP project.  The FHC facilities provide primary care for rural and 
underserved communities.  
 All patients with the diagnosis of hypertension and diabetes were screened for PAD and 
included in the study (n = 149) of these patients charts were randomly selected for secondary 
data analysis.  Diabetic and hypertensive patients that have not been screened for PAD were 
excluded.  The secondary data analysis evaluated HbA1c and level of PAD disease looking for a 
correlation. 
Measurement 
 The PAD-IQ provides information on the macro and micro circulation and allows for 
data storage to the cloud which can be retrieved easily for printing or sent electronically to a 
specialist, if one is needed (Vasamed SensiLase PAD-IQ, 2013).  Macro and micro circulation 
were measured using PAD-IQ, as well as patient HbA1cs from chart reviews.  The 
psychometrics of SPP were successfully demonstrated in the literature.  The comparative study 
of the SPP, ABI and TBI to multidetector-row computed tomography (MDCT) done by Okamoto 
et al. in 2006 demonstrated that SPP outperformed all in the hemodialysis (HD) patient 
population for above knee (AK) level disease.  SPP <50 mmHg was 100% sensitive for PAD 
detection and for below-the-knee (BK) level disease; SPP was 84.8% sensitive for PAD 
detection.  For AK level disease, ABI < 0.9 was insensitive for PAD and of the 13 of 72 limbs 
with ABI result of <0.9, sensitivity for ABI detecting peripheral arterial occlusive disease 
(PAOD) BK was only 29.9%.  Skin Perfusion Pressure was the most useful tool with respect to 
both sensitivity and specificity for early detection of PAD in renal population.  In 2009, Bailey 
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and Schechter conducted a validation study assessing wound healing prediction accuracy rate 
and PAD detection.  Wound healing prediction accuracy rates were SPP/PVR 93.2% (82/88) 
while TCOM/ABI was 63.9% (23/36).  Peripheral artery disease detection using SPP/PVR 
96.2% (50/52) and TCOM/ABI 61.5% (32/52).  Importantly, ABI was unable to be obtained 
bilaterally in 22% (22/100) of the sample population.  The SPP has been used successfully to 
assess the severity of limb ischemia and for the prediction of wound healing more accurately 
than can other noninvasive measurements.  
 The National Glycohemoglobin Standardization Program (NGSP) has been standardizing 
HbA1c instrument screening certification worldwide.  To obtain a NGSP certification, 
manufacturers have to meet the criteria of a 95% confidence level (Saudek et al., 2013).  In 2000, 
Rohlfing et al, demonstrated a sensitivity (83.4%) and specificity (84.4%) for detecting 
undiagnosed diabetes at a HBA1c cutoff of 1 SD above the normal mean of 7 (Rohlfing et al., 
2000).  The sensitivity and specificity of A1C ≥6.5% for detection of prevalent diabetes were 47 
and 98%, respectively against a single fasting glucose ≥126 mg/dl (Selvin, Steffes, Gregg, 
Brancati, & Coresh, 2013).  Selvin et al. (2013) repeated the testing 3 years later and the 
sensitivity improved to 67% and specificity remained high at 97% (Selvin et al., 2013).  
Glycohemoglobin has been successfully used to screen for diabetes.  
Data Collection Tool and Data Analysis 
Data Collection Tool and Procedure    
1. A list of clinic patients with the diagnosis of hypertension and type I or II diabetes 
was obtained from the selected study health center. 
2. A sample of patients’ charts from clinics was selected for the sample size of n=100 
using a random number generator.    
3. Charts were reviewed for documentation of HbA1c and peripheral flow. 
4. Patients who did not meet the criteria of HbA1c and SPP were discarded and others 
were selected from which the subject was removed.  
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5. Data were collected using a data collection tool (Appendix B).  
6. Data were analyzed using SPSS for descriptive and inferential statistics (Appendix 
A). 
 Data collected were analyzed based on age, sex, the level of disease, and were then 
compared to HbA1c levels for correlations.  Data analysis was conducted using SPSS for 
descriptive and inferential statistics.  The relationships between the variables was explored using 
Pearson correlation coefficient to assess the degree and direction of connection between the 
variables (Terry, 2012).  
Protection of Human Subjects 
Approval for this study was obtained on May 15th, 2014 from the institutional review 
board (IRB) for the Christus Health System and the study number assigned was 2014-008 
(Appendix D).  Permission to use the DSRIP data was obtained on May 15th, 2014 as part of the 
IRB approval.  The potential participants’ charts were obtained through data mining of clinic 
patients’ personal health information (PHI) with the diagnosis of diabetes and hypertension.  The 
HIPAA Privacy Rule was used since the data collected was de-identified; and this rule only 
applied to individually identifiable health information.  Because the data collected were de-
identified, the data was not considered to be personal health information (PHI) and could be used 
or disclosed without a signed authorization or an approved waiver of authorization.  All personal 
health information (PHI) was maintained according to electronic documentation and 
confidentiality policies of the Christus Spohn Health System.  Security within the electronic 
documentation system was restricted to the principal investigator.  All personal health 
information was coded with the study participant’s assigned study identification number and 
stored on an encrypted thumb drive locked in the office of the principal investigator. 
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 The objective of this project was to evaluate the relationship between level of PAD and 
HbA1c using secondary data obtained from the charts of patients within the clinic setting with 
the diagnosis of diabetes and hypertension.  The correlational study looked at the relationships 
among variables.  It provided a quantifiable methodology to analyze variables and add to the 
literature and knowledge of PAD.  This study provided a scientific foundation for early 
management and treatment of PAD.  The intended outcome of this study is to lead to improved 
PAD recognition, early intervention and the use of effective preventive methods.  Critical limb 
ischemia could be delayed and or prevented through effective screening methodologies.  The 
quality of life of this vulnerable population will be improved through early access to specialty 
care.  The cost of advanced PAD will be decreased and it can lead to the prevention of 
cardiovascular disease. 
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Section 4: Findings, Discussion, Results and Implications  
Findings and Results  
Of the 200 charts reviewed, 149 were selected based on the criteria of patients with 
diabetes and hypertension that had been screened for peripheral vascular disease using the 
PADIQ device.  There were 53 male participants or 35.6% of the sample and 96 female 
participants or 64.4%. More than half of the sample was between the ages of 31-60 years of age 
(79.9%).  See Table 2. 
Table 2 
Frequencies and Percentage for Dependent Variable 
 
 
 
 
 
 
 
 
 
 
Table 3 shows the descriptive statistics for levels of PAD among study participants.  The 
sample n=149 was assigned a level of disease from 1-4 based on SPP.  The participants with no 
disease were given a minimum score of 1(SPP > 70mm Hg).  Mild disease was given a score of 
2 (SPP 40-60 mm Hg), Moderate disease was given a score of 3 and Severe disease was given a 
score of 4(<30 mm Hg).  Left leg PAD has a mean of m = 1.42, with a SD = .80. Right leg PAD 
has a mean of m= 1.35 with a SD of .68. 
  n % 
 
Age Group 
 
 
30 or less 
31-60 
60 or greater 
 
7 
119 
23 
4.7 
79.9 
15.4 
Gender 
 
Male 
Female 
53 
96 
35.6 
64.4 
 
HBA1c  
 
7 or less 
7.1 to 10 
10 or greater 
 
48 
74 
27 
32 
49.6 
18.1 
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Table 3   
Mean and Standard Deviation for Peripheral Artery Disease (PAD) 
 
 N M SD Min Max 
Levels of 
PAD 
Lt leg 
RT Leg 
149 
 
149 
149 
 
 
1.42 
1.35 
 
 
.80 
.68 
1 
 
1 
1 
4 
 
4 
4 
 
 
As seen in Table 4, left PAD mild disease was n =26 or 17.4%.  Moderate disease n =8 or 
5.4% and severe disease n=7 or 4.7%.  Right PAD mild disease was n=26 or 17.4%.  Moderate 
disease n=10 or 6.7% and severe disease n=2 or 1.3%. 
Table 4 
Frequency and Percentage of PAD 
 
PAD levels n LT Pad % LT PAD n RT PAD %  RT PAD 
1 108 72.5 111 74.5 
2 26 17.4 26 17.4 
3 8 5.4 10 6.7 
4 7 4.7 2 1.3 
 
Descriptive statistics as listed in Table 5 shows a  mean age of  51.5 years with the 
standard deviation of 10.3 sample size n=149.  The mean HGA1c is 8.3 with a SD of 2.15.  Left 
PAD has a mean of m =1.42, with a SD = .80.  Right PAD has a mean of m = 1.35 with a SD of 
.68. 
 
21 
 
Table 5 
Descriptive Statistics   
  
 
 
Mean STD Deviation N Sex 
 
Age 
 
51.51 
 
10.30 
 
149 
 
M: 53   F: 96 
 
HbA1c 
 
8.3 
 
2.15 
 
149 
 
 
LT PAD 
 
1.42 
 
.80 
 
149 
 
 
RT PAD 
 
1.35 
 
.68 
 
149 
 
 
A Pearson’s correlation was run to determine the relationship between 149 patients’ 
HbA1c and level of PAD (see Table 2).  There was a significant relationship between HbA1c 
and LT PAD (r =.21, p=.009).  There was no relationship between HbA1c and RT PAD (r =.01, 
n =149, p =.90).  There was a significant relationship between HbA1c and age (r =.34, p =.00). 
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Correlations 
Table 6   
Correlations 
  Age HbA1c LT PAD RT PAD 
Age Pearson Correlation  -.336** -.018 .092 
 Sig. (2-tailed)  .000 .826 .265 
 N 149 149 149 149 
HbA1c Pearson Correlation -.336**  .212** .010 
 Sig. (2-tailed) .000  .009 .900 
 N 149 149 149 149 
LT PAD Pearson Correlation -.018 .212**  -.013 
 Sig. (2-tailed) .826 .009  .880 
 N 149 149 149 149 
RT PAD Pearson Correlation .092 .010 -.013 1 
 Sig. (2-tailed) .265 .900 .880  
 N 149 149 149 149 
 
** Correlation is significant at the 0.01 level (2-tailed). 
 
Summary of findings 
These findings support the importance of tight glycemic control, as well as early 
screening for PAD in high-risk populations.  Project findings added to the literature and 
knowledge about PAD and the significance of early screening in the prevention of cardiovascular 
events (CVD).    
Discussion of findings in the context of the literature 
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Findings have added to the literature about the importance of tight glycemic control in the 
prevention of peripheral artery disease. 
Routine screening for peripheral artery disease has been supported by the findings.  
Ultimately, these findings demonstrate that cardiovascular disease (CVD) prevention will be 
improved because of the link between PAD and CVD. 
Interpretation of Findings, and Implications for Evidence-Based Practice Policy 
Policies could be developed using the findings from this study and others which 
supported the need for early screening of high risk populations such as patients with diabetes, 
hypertension and hypercholesterolemia.  Policies regarding the population disparities could be 
supported by this study and others. 
 
Practice 
These studies could become the foundation for new practice guidelines to screen for PAD 
as a mechanism for the decrease in cardiovascular disease. There findings could be used to 
develop further studies about early screening for PAD in the diabetic population.  Also, early 
screening of high risk populations would be developed. 
Research 
 The Stetler model (2001) was used as the conceptual framework for this evidence-based 
project.  The framework facilitated the research question and literature review.  The data was 
analyzed using this frame work.  The results demonstrated that there was significance between 
HbA1c and PAD.  These results highlight the importance of glycemic control in an effort to 
prevent diabetic complications.  The significant strides made in the risk reduction of PAD and 
CVD through the behavior modification efforts of lessened tobacco use, a less sedentary lifestyle 
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and obesity will be applied to facilitate health promotion and decrease disease progression.  
Early recognition of PAD will provide opportunities for early interventions such glycemic 
control, blood pressure control and exercise to slow and decrease progression.  A decrease in 
disease progression will ultimately lead to: 
• Improved limb salvage  
• Decrease in the number of limb amputations 
• Decrease in the psychological effects of PAD 
• Decrease in the medical and surgical cost of interventions 
            •  Improved CVD prevention 
Results of this study can be used to further support other research into early screening for 
PAD, ultimately leading to a change in the current practice of only screening patients that are 
symptomatic.  The success of asymptomatic screening would lead to a practice change which, 
ultimately, will improve patient care and clinical outcomes.  The main strength of this project is 
its innovative focus - a comparison of the values of glucose control and severity of peripheral 
artery disease (PAD).  Screening of asymptomatic patients is not supported in the literature; 
however, early PAD identification will positively impact the prevalence and incidence of severe 
cardiovascular disease.  Early screening will have a significant impact by providing information 
about the severity of PAD allowing for the initiation of therapy to improve outcomes, save limbs 
and lives. 
This project involved secondary data analysis looking for correlations between the two 
variables of glycos-hemoglobin (HbA1c) and PAD.  The relationships discovered could add to 
the literature and provide a foundation for more research in this field.  Secondary data analysis 
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relies on the data available from the original EBP, which is screening patients with diabetes and 
hypertension for PAD.  Limitations of the plan included sample size may not be large enough for 
statistical significance.  Ideally, this project should be a longitudinal one, so that the full value of 
early screening can be obtained.  Baseline assessments of PAD and HbA1c should be obtained 
and the participants followed over time to see the full impact of screening and early intervention.  
Project strengths and limitations 
 Strengths.  The strength of the project was its unique look at peripheral arterial disease 
and correlation with glycos-hemoglobin (HBA1c).  This perspective has not been studied 
previously and it will add important viewpoints and results to the literature on this subject.  
 
Analysis of Self 
As a practitioner 
My nursing focus  has always been a clinical or practical one.  Research that can be 
applied to practice for improved clinical outcomes has been a passion of mine. The DNP 
prepared leader or practitioner will gain skills that  enables them to communicate effectively on 
behalf of the patient and the clinician at the bedside.  A doctorate that supports practice can 
bridge the gap between scientific research and the application of the evidence to the care of 
patients for improved outcomes.  There needs to be a foundation for  practice,  and nurses that 
are PHD, DNS or DNSc prepared gain the knowledge to drive research which facilitates the 
credibility of nursing science.  It is highly beneficial to create a foundation for the nursing 
profession. Doctoral nurses  acquire  additional knowledge to drive research which  facilitates 
the credibility of nursing practice. 
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The DNP will allow for the continuation of my passion for nursing; knowledge is a 
powerful tool that can be used to increase my credibility as a clinical expert.  As we move 
forward with Obamacare and the Affordable Care Act, we will need to effectively manage 
patients with a focus on quality and fiscal responsibility.  The DNP practitioner role positions 
advanced practice nurses (APNs) to assist in alleviating the burden of managing complex 
patients with many core morbidities.  DNP-prepared nurses, have many opportunities  to utilize 
an enhanced skill set which includes clinical expert, teacher, patient advocate and nurse 
executive.  A DNP provides  the foundation to go out in the world and make a difference in 
healthcare outcomes.  
  
This project in future professional development 
Peripheral artery disease prevention  has a global impact.  The literature does not support 
the screening of asymptomatic patients for PAD; however, as I discuss my project and I share the  
literature, I have begun to have many insights during moments with my peers.  I foresee this 
project continuing past my DNP and my becoming an advocate for the prevention of PAD and 
campaigning to save limbs.  This project has had many barriers and I have had to use leadership, 
as well as communication skills, to navigate for a solution.  The organizational IRB process 
forced me to persevere in order to obtain approval. 
Currently, less than 1% of all nurses in America have a doctoral degree and when I 
reflect on that statistic, I am excited and humble to discover that I am one of the few.  The 
responsibility of a doctorate is an important one for healthcare policy and outcomes.  There are 
many opportunities available for my skill set and I will continually evaluate and ensure these 
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skills are being used to collaborate and advocate for constantly improving nursing and patient 
outcomes.   
Ethics is very important to me academically and personally.  Ethics are a part of my value 
system and it is essential that I maintain the ethical standards and value system with which I was 
raised.  The DNP essential competencies provide us with a foundation to impact healthcare on 
many levels.  The science of nursing practice is advanced by looking at the scientific 
underpinnings for practice (AACN, 2006).  Walden students have the vision and the mission to 
advance their chosen profession and work towards improving the environment in which we work 
and live.  Our acquired skills will be used to manage the challenges of society. 
According to the AACN, healthcare systems will be improved through leadership and 
quality initiatives; the DNP prepared Walden graduate will have the necessary tools to create and 
shape future health policies.  Patient care will be advanced using improved technology.  Clinical 
outcomes will be improved through the use of evidenced-based practice.  DNPs have the skill set 
to advocate for better patient outcomes through interprofessional collaborations (AACN, 
2006).  Health care policies and health care performed will be transformed and thus lead to a 
healthier population.   
The AACN essentials and Walden’s vision for its students will be utilized in my practice 
as I advocate for better health for patients.  My passion is prevention and I will use my honed 
skills to advocate for health care policies that focus on disease prevention.  While in the DNP 
program, my leadership skills will be further developed and I will use them to advance nursing 
professionally through population education and the education of future nursing students.  
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Summary and Conclusion 
  Peripheral artery disease has significant correlations with other cardiovascular events 
and early recognition has the potential to impact health care clinically by providing opportunities 
for early interventions, such as behavior modifications and cardiac rehabilitation.  Furthermore, 
less invasive interventions such as angioplasty will be available to prevent critical limb ischemia 
(CLI) and limb amputations.  The benefits of early recognition of these diseases will contribute 
to improving clinical outcomes through the creation of opportunities for aggressive management 
of the risk factors leading to this disease. 
The direct health care cost of PAD is between $164 and $290 billion dollars per year and 
the ability to decrease these cost will free up funds that will become available for other health 
care areas (SAGE, 2010),. 
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Section 5:   Scholarly Product 
Project Summary and Evaluation Report 
Peripheral artery disease (PAD) affects 8 to 10 million Americans and it is expected to 
increase as the population ages and chronic diseases continue to rise (Hirsch, Hartman, Town & 
Virnig, 2008).  Peripheral artery disease is defined as atherosclerosis of the abdominal aorta, 
iliac, and lower-extremity arteries (Olin & Sealove, 2010).  According to the Sage Group (2010), 
the direct cost of PAD in the United States is estimated to be between $164 and $290 billion.  
The U.S. Preventive Services Taskforce (USPSTF) defines PAD as a manifestation of systemic 
atherosclerosis that has demonstrated a significant correlation with other atherosclerotic, 
cardiovascular diseases (CVD) and cardiac related events (USPSTF, 2013).  A high percentage 
of the PAD population is undiagnosed before a serious cardiovascular event; therefore, the 
ability to screen and diagnose this disease could have a dramatic impact on the efforts to 
decrease cardiovascular disease.  Individuals with PAD have a three to five times increased risk 
of CVD mortality when compared to people that do not have PAD (Criqui et al., 1992). 
Additionally, the consistent correlation between PAD and future CVD events has 
influenced the American Heart Association (AHA) and the National Cholesterol Education 
Program (NCEP) to establish recommendations for intensive atherosclerotic risk factor reduction 
for PAD and CVD patients (NCEP, 1993).  Early identification of patients with PAD has the 
potential to impact CVD and, in doing so, to create opportunities for aggressive management of 
the risk factors leading to this disease.  Common disease and lifestyle factors have been directly 
linked to PAD and CVD; therefore, health promotion has been focused on risk reduction (AHA, 
2013). 
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Significant strides have been made in the risk reduction of this disease through 
modification of health behaviors such as tobacco use, sedentary lifestyle and obesity.  Disease 
management of hypertension, diabetes and hyperlipidemia has proven to have significant impact 
on atherosclerosis (Olin & Sealove, 2010).  Secondary prevention involves screening for diseases 
before they have had an impact on the individual.  Screening high-risk patients with diabetes and 
hypertension who are asymptomatic for PAD is an example of secondary prevention.  The 
ultimate goal of prevention is to impact the prevalence and incidence of disease.  
Method 
The primary research method used in this project was a correlational retrospective cohort 
study.  This correlational retrospective cohort study evaluated the impact of early screening for 
PAD disease outcomes along with the relationship between HbA1cs and severity of disease. The 
Delivery System Reform Incentive Payment (DSRIP) project is part of the government’s 
initiative to improve patient outcomes and the data collected for this project is available in the 
public domain.  As part of the DSRIP initiative, clinic patients with diabetes and hypertension 
were screened using the PAD-IQ.  This device is noninvasive and uses segmental pressure to 
obtain Skin Perfusion Pressure (SPP) to provide a quantitative evaluation of microcirculatory 
perfusion of the skin.  All patients with the diagnosis of hypertension and diabetes were screened 
for PAD and included in the study (n = 149) of these patients charts were randomly selected for 
secondary data analysis.  Diabetic and hypertensive patients that have not been screened for PAD 
were excluded.  The secondary data analysis evaluated HbA1c and level of PAD disease looking 
for a correlation. 
Data collected was analyzed based on age, sex, and for the level of disease and compared 
to HbA1c levels for correlations.  Data analysis was conducted using SPSS for descriptive and 
inferential statistics.  
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Results 
Two hundred charts were reviewed and n=149 were selected based on the criteria of 
patients with diabetes and hypertension that had been screened for peripheral vascular disease 
using the PADIQ device.  Male patients were 53 and female were 96, with an age range of 24 to 
85.  Descriptive statistics listed in Table 2 shows a  mean age of  51.5 with the standard deviation 
( SD)of 10.3 sample size n=149.  The mean HGA1c is 8.3 with a SD of 2.15.  Left PAD has a 
mean of m=1.42, with a SD = .80.  Right PAD has a mean of m= 1.35 with a SD of .68. 
A Pearson’s correlation was run to determine the relationship between 149 patients’ 
HbA1c and level of peripheral artery disease (PAD) as shown in Table 3.  There was a 
significant relationship between HbA1c and LT PAD (r=.21, p=.009).  There was no relationship 
between HbA1c and RT PAD (r=.01, n=149, p=.90).  There was a significant relationship 
between HbA1c and age (r=.34, p=.00). 
Discussion 
 The results demonstrated that there was significance between HbA1c and PAD.  These 
results highlight the importance of glycemic control in an effort to prevent diabetic 
complications.  The significant strides made in the risk reduction of PAD and CVD through the 
behavior modification efforts of lessened tobacco usage, decreased sedentary lifestyles and 
obesity will be applied to facilitate health promotion and decrease disease progression.  Early 
recognition of PAD will provide opportunities for early interventions such glycemic control, 
blood pressure control and exercise to slow and decrease progression.  A decrease in disease 
progression will ultimately lead to: 
• Improved limb salvage Improved CVD prevention 
• Decrease in the number of limb amputations 
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• Decrease in the psychological effects of PAD 
• Decrease in the medical and surgical cost of interventions 
• Improved CVD prevention 
 Results of this study can be used to further support other research into early screening for 
PAD, ultimately leading to a change in the current practice of only screening patients that are 
symptomatic.  The success of asymptomatic screening would lead to a practice change, which, 
ultimately, will improve patient care and clinical outcomes.  The main strength of this project is 
its innovative focus - a comparison of the values of glucose control and severity of peripheral 
artery disease (PAD).  Screening of asymptomatic patients is not supported in the literature; 
however, early PAD identification will positively impact the prevalence and incidence of severe 
cardiovascular disease.  Early screening will have a significant impact by providing information 
about the severity of PAD allowing for the initiation of therapy to improve outcomes and save 
limbs and lives. 
This study involved secondary data analysis looking for correlations between the two 
variables of glycos-hemoglobin (HbA1c) and PAD.  The relationships discovered could add to 
the literature and provide a foundation for more research in this field.  Secondary data analysis 
relies on the data available from the original EBP, which is screening patients with diabetes and 
hypertension for PAD.  Limitations of the plan included sample size may not be large enough for 
statistical significance.  Ideally, this project should be a longitudinal one, so that the full value of 
early screening can be obtained.  Baseline assessments of PAD and HbA1c should be obtained 
and the participants followed over time to see the full impact of screening and early intervention. 
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Summary 
Peripheral artery disease (PAD) has significant correlations with other cardiovascular 
events and early recognition has the potential to impact health care clinically by providing 
opportunities for early interventions, such as behavior modifications and cardiac rehabilitation.  
Furthermore, less invasive interventions such as angioplasty will be available to prevent critical 
limb ischemia (CLI) and limb amputations.  The benefits of early recognition of these diseases 
will contribute to improving clinical outcomes through the creation of opportunities for 
aggressive management of the risk factors leading to this disease. 
The quality of life of this vulnerable population will be improved through early access to 
specialty care.  
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Appendix A 
Data Collection Tool  
Study ID SEX SPP HbA1c Lt PAD RT PAD 
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Appendix B 
Study Timeline 
Table 7 
Study Timeline 
 
Date Activity 
August  2014 – December 2014 IRB Approval, Notify providers of    
study 
January  2015 – March2015 Collect data 
March 2015– April 2015 Comprise statistical analysis 
September –  2015 Complete capstone project 
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Appendix C 
Permission to Conduct Study 
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Appendix D 
IRB Certificate  
 
Dear Ms. Gordon, 
  
This email is to notify you that the Institutional Review Board (IRB) confirms that your 
study entitled, "Peripheral Artery Disease Screening," meets Walden University’s ethical 
standards. Our records indicate that you will be analyzing data provided to you by 
Christus Spohn as collected under its oversight. Since this study will serve as a Walden 
doctoral capstone, the Walden IRB will oversee your capstone data analysis and results 
reporting. The IRB approval number for this study is 12-03-14-0393878. 
  
This confirmation is contingent upon your adherence to the exact procedures described 
in the final version of the documents that have been submitted to IRB@waldenu.edu as 
of this date. This includes maintaining your current status with the university and the 
oversight relationship is only valid while you are an actively enrolled student at Walden 
University. If you need to take a leave of absence or are otherwise unable to remain 
actively enrolled, this is suspended. 
  
If you need to make any changes to your research staff or procedures, you must obtain 
IRB approval by submitting the IRB Request for Change in Procedures Form.  You will 
receive confirmation with a status update of the request within 1 week of submitting the 
change request form and are not permitted to implement changes prior to receiving 
approval.  Please note that Walden University does not accept responsibility or liability 
for research activities conducted without the IRB's approval, and the University will not 
accept or grant credit for student work that fails to comply with the policies and 
procedures related to ethical standards in research. 
  
When you submitted your IRB materials, you made a commitment to communicate both 
discrete adverse events and general problems to the IRB within 1 week of their 
occurrence/realization.  Failure to do so may result in invalidation of data, loss of 
academic credit, and/or loss of legal protections otherwise available to the researcher. 
  
Both the Adverse Event Reporting form and Request for Change in Procedures form 
can be obtained at the IRB section of the Walden 
website: http://academicguides.waldenu.edu/researchcenter/orec 
  
Researchers are expected to keep detailed records of their research activities (i.e., 
participant log sheets, completed consent forms, etc.) for the same period of time they 
retain the original data.  If, in the future, you require copies of the originally submitted 
IRB materials, you may request them from Institutional Review Board. 
  
Please note that this letter indicates that the IRB has confirmed your study meets 
Walden University’s ethical standards.  You may not begin the doctoral study analysis  
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Walden IRB Approval, continued 
 
 
phase of your doctoral study, however, until you have received the Notification of 
Approval to Conduct Research e-mail.  Once you have received this notification by 
email, you may begin your study’s data analysis. 
  
Both students and faculty are invited to provide feedback on this IRB experience at the 
link below: 
  
http://www.surveymonkey.com/s.aspx?sm=qHBJzkJMUx43pZegKlmdiQ_3d_3d 
  
Sincerely, 
Libby Munson 
Research Ethics Support Specialist 
Office of Research Ethics and Compliance 
Email: irb@waldenu.edu 
Fax: 626-605-0472 
Phone: 612-312-1283 
  
Office address for Walden University: 
100 Washington Avenue South, Suite 900 
Minneapolis, MN 55401 
 
 
 
 
 
 
 
 
 
 
 
 
